SNGX Stock Catalyst: FDA Grants Soligenix Orphan Drug Designation for Behçet's Disease Treatment

Soligenix, Inc. (Nasdaq: SNGX) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its therapeutic candidate aimed at treating Behçet's Disease. This designation provides Soligenix with certain benefits, including tax credits for clinical trials and potential market exclusivity upon approval.

The Orphan Drug Designation is a critical step for Soligenix as it progresses its candidate through the regulatory process. The company's free float stands at 9,362,300 shares, with 10,086,100 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.